Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | March 26, 2019 | March 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date March 26, 2019 · Filed March 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 161,540 |
Ending reported balance
After 2019-03-26 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-26 · Exercise / conversion · Acquired 6,000 · Balance 137,540 Row 2 · 2019-03-26 · Exercise / conversion · Acquired 12,000 · Balance 149,540 Row 3 · 2019-03-26 · Exercise / conversion · Acquired 12,000 · Balance 161,540 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.34 · Expires 2025-06-03 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-26 · Exercise / conversion · Disposed 6,000 · Balance 0 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.65 · Expires 2027-06-07 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-03-26 · Exercise / conversion · Disposed 12,000 · Balance 0 F1: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.05 · Expires 2026-06-08 | Direct | 0 |
Reported balance
After 2019-03-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-03-26 · Exercise / conversion · Disposed 12,000 · Balance 0 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $19.05 | $0.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · derivative · entry 6 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · derivative · entry 5 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · derivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $19.05 | $228,600.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 12,000 | $28.65 | $343,800.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 22:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.34 | $110,040.00 |
DisclosureSEC source: 0001209191-19-021482 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001209191-18-050650 · doc4.xml · derivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,700 | $57.60 | $97,920.00 |
DisclosureSEC source: 0001209191-18-050650 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,540 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $57.55 to $57.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,300 | $57.19 | $245,917.00 |
DisclosureSEC source: 0001209191-18-050650 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,240 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $56.55 to $57.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 20:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.34 | $110,040.00 |
DisclosureSEC source: 0001209191-18-050650 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046244 · doc4.xml · derivative · entry 5 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 272 | $61.21 | $16,649.12 |
DisclosureSEC source: 0001209191-18-046244 · doc4.xml · nonDerivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,540 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $61.10 to $61.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,028 | $60.36 | $122,410.08 |
DisclosureSEC source: 0001209191-18-046244 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,812 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $60.10 to $60.90. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,700 | $59.60 | $220,520.00 |
DisclosureSEC source: 0001209191-18-046244 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $59.10 to $60.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 20:48 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.00 | $108,000.00 |
DisclosureSEC source: 0001209191-18-046244 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042396 · doc4.xml · derivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2024-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $67.71 | $406,260.00 |
DisclosureSEC source: 0001209191-18-042396 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,540 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $67.25 to $68.175. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2018 Filed Jul 11, 2018 22:59 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $18.00 | $108,000.00 |
DisclosureSEC source: 0001209191-18-042396 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-18-037338 · doc4.xml · derivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $57.48 | $344,880.00 |
DisclosureSEC source: 0001209191-18-037338 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,540 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $57.05 to $58.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $9.78 | $58,650.00 |
DisclosureSEC source: 0001209191-18-037338 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $55.30 | $0.00 |
DisclosureSEC source: 0001209191-18-036520 · doc4.xml · derivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-05 F2 · derivative.exercise_date: Options vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 23:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-036520 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,540 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:34 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001209191-18-029578 · doc4.xml · derivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2023-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:34 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $47.10 | $282,600.00 |
DisclosureSEC source: 0001209191-18-029578 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $46.80 to $47.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:34 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $9.78 | $58,650.00 |
DisclosureSEC source: 0001209191-18-029578 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-18-024694 · doc4.xml · derivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2022-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,600 | $46.80 | $215,280.00 |
DisclosureSEC source: 0001209191-18-024694 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $46.50 to $47.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,400 | $45.91 | $64,274.00 |
DisclosureSEC source: 0001209191-18-024694 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,440 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $45.50 to $46.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:21 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $5.95 | $35,700.00 |
DisclosureSEC source: 0001209191-18-024694 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · derivative · entry 9 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,400 | $56.27 | $78,778.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 7 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $56.05 to $56.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,600 | $55.55 | $255,530.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 6 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,240 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $55.00 to $55.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.50 | $21,000.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 5 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · derivative · entry 8 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully vested. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,900 | $55.50 | $160,950.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $55.30 to $55.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,907 | $54.62 | $104,160.34 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,740 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $54.20 to $55.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,193 | $53.77 | $64,147.61 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,647 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $53.20 to $54.175. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 22:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.50 | $21,000.00 |
DisclosureSEC source: 0001209191-18-010955 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · derivative · entry 6 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $47.32 | $283,920.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · nonDerivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $47.00 to $47.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · derivative · entry 5 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $47.18 | $283,080.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $46.80 to $47.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 30, 2017 Filed Dec 5, 2017 01:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $2.90 | $17,400.00 |
DisclosureSEC source: 0001209191-17-063687 · doc4.xml · nonDerivative · entry 1 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · derivative · entry 6 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $47.93 | $287,580.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · nonDerivative · entry 4 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 6,000 | $3.60 | $21,600.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · nonDerivative · entry 3 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · derivative · entry 5 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 01:27 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,000 | $46.78 | $280,680.00 |
DisclosureSEC source: 0001209191-17-051481 · doc4.xml · nonDerivative · entry 2 Routti Jorma · CIK 0001621330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,840 F1 · shares: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.